According to the offshore protein announcement, the cumulative closing price deviation value of the company's stock exceeded 30% for 3 consecutive trading days on August 19, August 20, and August 21, 2026, and there were 3 such abnormal fluctuations in 10 consecutive trading days from August 6 to August 21, which is a serious abnormal fluctuation in stock trading. After verification, the company, controlling shareholders, and actual controllers have no important information that should be disclosed, and production and operation are normal. In 2025, the company's revenue was 146 million yuan, up 14.80% year on year, with a net loss of 777.8834 million yuan; revenue for the first quarter of 2026 was 37.2467 million yuan, up 11.37% year on year, with a net loss of 106.044 million yuan; net loss is expected to be 26.5 million yuan to 29.5 million yuan for the half year of 2026, an increase over the same period last year. As of the close of trading on August 21, 2026, the company's market sales ratio was 37.69, higher than comparable companies in the same industry, reminding investors to be aware of transaction risks.

According to the offshore protein announcement, the cumulative closing price deviation value of the company's stock exceeded 30% for 3 consecutive trading days on August 19, August 20, and August 21, 2026, and there were 3 such abnormal fluctuations in 10 consecutive trading days from August 6 to August 21, which is a serious abnormal fluctuation in stock trading. After verification, the company, controlling shareholders, and actual controllers have no important information that should be disclosed, and production and operation are normal. In 2025, the company's revenue was 146 million yuan, up 14.80% year on year, with a net loss of 777.8834 million yuan; revenue for the first quarter of 2026 was 37.2467 million yuan, up 11.37% year on year, with a net loss of 106.044 million yuan; net loss is expected to be 26.5 million yuan to 29.5 million yuan for the half year of 2026, an increase over the same period last year. As of the close of trading on August 21, 2026, the company's market sales ratio was 37.69, higher than comparable companies in the same industry, reminding investors to be aware of transaction risks.